ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
February 12, 2020
crowd of women
February 12, 2020
Categories
  • Trial Results

Trial Results: New TAILORx data shows chemotherapy benefit for women at high risk of breast cancer recurrence

The TAILORx trial answers questions about when to use chemotherapy to treat the most common type of breast cancer.
Do you like it?
0 Read more
February 10, 2020
man with kidney pain
February 10, 2020
Categories
  • Ongoing Trials

Ongoing Trial: The PROSPER RCC kidney cancer trial seeks to transform treatment for patients with renal cell carcinoma

This trial is comparing immune system therapy before and after surgery to surgery alone.
Do you like it?
0 Read more
February 9, 2020
green awareness ribbon hope
February 9, 2020
Categories
  • New Trials

Now Enrolling: Trial EA4181 is comparing three different chemotherapy treatments for newly diagnosed mantle cell lymphoma

Right now, researchers do not know the ideal treatment for people with newly diagnosed mantle cell lymphoma.
Do you like it?
0 Read more
February 4, 2020
Gerald Green headshot
February 4, 2020
Categories
  • Editorials

Planning early for late effects

Advocate Gerald Green shares his perspective on how to anticipate the late effects of cancer—and its treatment. Late effects can appear months or even years after patients finished therapy.
Do you like it?
Read more

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Tags

Acute lymphoblastic leukemia Adolescents and young adults Advocacy Bladder cancer Breast cancer Caregiving Communication De-escalation Head and neck cancer Health equity HER2+ breast cancer Immune system therapy Immunotherapy In memory Kidney cancer Leukemia Lung cancer Lymphoma Mammography Mantle cell lymphoma Melanoma Multiple myeloma Myeloma NCI-MATCH Nose and sinus cancer Pancreatic cancer Pancreatic cysts Patient care Personalized medicine Personalized screening Personalized treatment Precision medicine Prevention Prostate cancer Renal cell carcinoma Research results Sarcoma Screening Side effects Squamous cell carcinoma Surveillance Survivorship Symptom management Targeted therapy Throat cancer

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc